Physician profile
James E Milner
NPI 1669460739
$2,151.97
in general payments reported to CMS, 2019-2025
31 companies · $25.00 in 2025
The $25.00 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $440 · 2021: $487 · 2022: $103 · 2025: $25.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $380.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $253.45 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $252.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $216.39 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $96.67 | 2019-2022 | |
| Astellas Pharma US INC | $94.93 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $86.13 | 2019-2021 | |
| Eisai INC. | $70.11 | 2019-2020 | |
| Janssen Biotech, INC. | $67.22 | 2019-2022 | |
| Daiichi Sankyo INC. | $62.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.55 | 2019-2020 | |
| Tesaro, INC. | $50.45 | 2019 | |
| Seagen INC. | $44.19 | 2019-2022 | |
| Array Biopharma INC | $42.89 | 2020-2021 | |
| Genentech USA, INC. | $42.61 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.03 | 2019-2022 | |
| Taiho Oncology, INC. | $29.61 | 2021 | |
| Lilly USA, LLC | $29.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.08 | 2020-2021 | |
| Pfizer INC. | $27.78 | 2020-2021 | |
| Incyte Corporation | $25.19 | 2020-2021 | |
| Genmab U.S., INC. | $25.00 | 2025 | Epkinly |
| Clovis Oncology, INC. | $23.18 | 2019-2020 | |
| Blueprint Medicines Corporation | $16.39 | 2022 | |
| Coherus Oncology, INC. | $16.06 | 2020 | |
| Myovant Sciences INC. | $15.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $14.45 | 2019 | |
| Abbvie INC. | $12.95 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Milner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.